| Nov 11 |
Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting
|
| Nov 9 |
Chimerix Third Quarter 2024 Earnings: Misses Expectations
|
| Nov 8 |
Q3 2024 Chimerix Inc Earnings Call
|
| Nov 8 |
Chimerix Inc (CMRX) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid Financial ...
|
| Nov 8 |
Chimerix, Inc. (CMRX) Q3 2024 Earnings Call Transcript
|
| Nov 7 |
Chimerix (CMRX) Reports Q3 Loss, Lags Revenue Estimates
|
| Nov 7 |
Chimerix: Q3 Earnings Snapshot
|
| Nov 7 |
Chimerix GAAP EPS of -$0.26 misses by $0.02, revenue of $0.02M misses by $0.29M
|
| Nov 7 |
Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update
|
| Nov 6 |
Chimerix Q3 2024 Earnings Preview
|
